The US Food and Drug Administration (FDA) conducted an inspection of pharmaceutical company Lupin's manufacturing facility in Ankleshwar, Gujarat, and issued Form 483 with two observations. An FDA Form 483 is issued when an investigator observes any violations of the Food, Drug and Cosmetic Act and related acts. The company's shares closed at ₹2,344.45 on Friday.